Insys Therapeutics, Inc., a specialty pharma preparing to commercialize a fentanyl spray to treat breakthrough cancer pain, filed on Wednesday with the SEC to raise up to $55 million in an initial public offering. The Phoenix, AZ-based company, which was founded in 1990 and has yet to generate revenue, plans to list on the NASDAQ under the symbol INRX. Wells Fargo Securities and JMP Securities are the lead underwriters on the deal, for which pricing terms and timing were not disclosed.
